arrow_back Trending Legislation
Share share

US Drug Production Report: Less Import, Greater Health Security

This bill aims to enhance public health security by analyzing and removing barriers to domestic manufacturing of essential medicines and medical devices. This means less reliance on imports in the future, potentially ensuring more stable supplies of critical medical products, especially during crises. The government is tasked with preparing a report outlining how to improve domestic production.
Key points
The U.S. government will prepare a report on challenges in domestic manufacturing of drugs and medical devices.
The goal is to reduce reliance on imported critical medical products, especially vital during health emergencies.
The report will recommend specific strategies to boost domestic production and ensure stable supplies.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
To direct the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs, to submit to Congress a report on barriers, including regulatory inefficiencies, to domestic manufacturing of active pharmaceutical ingredients, finished drug products, and devices, and for other purposes.
Print number: HR 6710
Sponsor: Rep. Herrell, Yvette [R-NM-2]
Process start date: 2022-02-11
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about US Drug Production Report: Less Import, Greater Health Security

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is HR 6710.

Which chamber initiated this legislation?

This legislation was initiated in the House of Representatives.

When did the legislative process begin?

The process officially started on 2022-02-11.

What are the main provisions?

Key points include:

  • The U.S. government will prepare a report on challenges in domestic manufacturing of drugs and medical devices.
  • The goal is to reduce reliance on imported critical medical products, especially vital during health emergencies.
  • The report will recommend specific strategies to boost domestic production and ensure stable supplies.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Rep. Herrell, Yvette [R-NM-2].

What is the latest detailed status?

The latest detailed status is: Referred to the Subcommittee on Health.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-28.

Analysis and Potential Impact of HR 6710

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health